Clinical efficacy and safety of transcutaneous acupoint electrical stimulation combined with proton pump inhibitors in the treatment of laryngopharyngeal reflux disease:a randomized controlled trial

The First Affiliated Hospital of Anhui Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Aged >= 18 years;
•2. Symptoms of foreign body sensation in the throat for more than 6 weeks, continuous throat clearing, hoarseness, fatigue of pronunciation, sore throat, chronic cough, dyspnea and other symptoms;
•3. Patients with RSI>13 points and/or RFS>7 points, Dx-ph monitoring diagnosed as acid reflux;
•4. The patient signs an informed consent form and agrees to participate in the clinical trial.

•1. The diagnosis is considered to be pharyngeal discomfort caused by bacterial or viral pharyngitis;
•2. Upper gastrointestinal endoscopy or laryngoscopy found erosive gastroesophageal reflux, laryngeal cancer, esophageal cancer, gastric cancer and other diseases;
•3. History of esophagus or stomach surgery, history of neck radiotherapy;
•4. Severe liver, kidney and other organ dysfunction, unable to tolerate medications or allergic to medications;
•5. Have used proton pump inhibitor therapy or other research drugs in the previous month;
•6. Patients who are pregnant or breast-feeding;
•7. RSI scale score (excluding the ninth item) <10 points;
•8. Patients taking clopidogrel or warfarin;
•9. Contraindications for transcutaneous electrical acupoint stimulation (TEAS): such as acupuncture points to stimulate skin rash or local infection or implantation of a pacemaker or defibrillator, electrode pads cause skin allergies or itching, etc. and patients suffering from acute diseases, infectious diseases, malignant tumors, cardiovascular and cerebrovascular diseases or other malignant diseases.

发起方